Sarepta Therapeutics (SRPT) Stock Price Down 6.2%
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares traded down 6.2% during trading on Thursday . The stock traded as low as $57.13 and last traded at $57.17. 1,162,212 shares changed hands during mid-day trading, a decline of 34% from the average session volume of 1,771,082 shares. The stock had previously closed at $60.95.
Several research analysts recently commented on the company. Barclays reaffirmed a “hold” rating and issued a $55.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, January 23rd. William Blair reissued an “outperform” rating on shares of Sarepta Therapeutics in a report on Monday, February 5th. Royal Bank of Canada assumed coverage on Sarepta Therapeutics in a report on Monday, January 22nd. They set an “outperform” rating for the company. Leerink Swann reissued an “outperform” rating and set a $77.00 price objective on shares of Sarepta Therapeutics in a report on Friday, January 19th. Finally, Zacks Investment Research raised Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and seventeen have issued a buy rating to the stock. Sarepta Therapeutics currently has a consensus rating of “Buy” and an average target price of $64.65.
The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $3,440.00, a PE ratio of -27.03 and a beta of 1.49.
A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its position in Sarepta Therapeutics by 0.9% in the fourth quarter. BlackRock Inc. now owns 6,286,343 shares of the biotechnology company’s stock worth $349,773,000 after purchasing an additional 58,433 shares during the period. Vanguard Group Inc. increased its position in Sarepta Therapeutics by 4.0% in the second quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock worth $143,572,000 after purchasing an additional 162,543 shares during the period. Jennison Associates LLC grew its position in shares of Sarepta Therapeutics by 0.6% during the 4th quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock worth $63,998,000 after buying an additional 6,357 shares during the period. Eagle Asset Management Inc. grew its position in shares of Sarepta Therapeutics by 26.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,006,222 shares of the biotechnology company’s stock worth $49,858,000 after buying an additional 207,810 shares during the period. Finally, Emerald Advisers Inc. PA grew its position in shares of Sarepta Therapeutics by 2.1% during the 3rd quarter. Emerald Advisers Inc. PA now owns 893,484 shares of the biotechnology company’s stock worth $40,528,000 after buying an additional 18,077 shares during the period. Hedge funds and other institutional investors own 81.97% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.